Traders Purchase High Volume of Keros Therapeutics Call Options (NASDAQ:KROS)

Keros Therapeutics, Inc. (NASDAQ:KROS) was the recipient of some unusual options trading on Thursday. Stock traders acquired 2,688 call options on the company. This is an increase of 3,532% compared to the average daily volume of 74 call options.

Institutional Trading of Keros Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. raised its stake in Keros Therapeutics by 14.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock valued at $15,105,000 after acquiring an additional 32,492 shares during the period. Assenagon Asset Management S.A. bought a new position in Keros Therapeutics in the 2nd quarter valued at about $1,118,000. Intech Investment Management LLC bought a new position in Keros Therapeutics in the 3rd quarter valued at about $603,000. Bank of New York Mellon Corp lifted its position in Keros Therapeutics by 18.8% during the second quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock worth $5,410,000 after acquiring an additional 18,755 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its position in shares of Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after purchasing an additional 577,220 shares during the last quarter. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Stock Performance

KROS opened at $18.43 on Friday. The business’s 50-day simple moving average is $59.95 and its 200 day simple moving average is $52.83. Keros Therapeutics has a 52-week low of $15.67 and a 52-week high of $73.00. The firm has a market capitalization of $746.54 million, a PE ratio of -3.54 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $0.39 million for the quarter. During the same quarter in the prior year, the business earned ($1.33) earnings per share. The company’s quarterly revenue was up 4750.0% on a year-over-year basis. On average, research analysts forecast that Keros Therapeutics will post -5.26 earnings per share for the current year.

Analyst Ratings Changes

KROS has been the topic of a number of research reports. William Blair lowered shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday. TD Cowen lowered shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday. Cantor Fitzgerald restated an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a research note on Thursday, November 7th. Finally, Bank of America lowered their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research report on Thursday, September 12th. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Keros Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $95.22.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.